Fenwick and Goodwin represented Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
Royalty Pharma’s Acquisition of Royalty Interest in SPINRAZA and Pelacarsen from Ionis
Royalty Pharma’s Acquisition of Royalty Interest in TRELEGY ELLIPTA
Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
Royalty Pharma’s Acquisition of Theravance Respiratory Company
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...
HIBio’s License Agreements with MorphoSys AG
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
Sichuan Kelun-Biotech Biopharmaceutical’s License Agreement with Merck
Goodwin Procter advised Sichuan Kelun-Biotech Biopharmaceutical Co. on the deal. Sichuan Kelun-Biotech Biopharmaceutical Co. announced its exclusive license and collaboration agreement with Merck for ex-China development...
Generate Biomedicines’ Research Collaboration Agreement with Amgen
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
MorphoSys’ $1.7 Billion Acquisition of Constellation Pharmaceuticals
Wachtell, Lipton, Rosen & Katz and Willkie Farr & Gallagher advised Constellation on the deal. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty...
Cerevel Therapeutics’ $125 Million Non-dilutive Financing Transaction for Tavapadon
Goodwin Procter LLP advised Cerevel Therapeutics on the deal. Ropes & Gray represented Bain Capital, while Wyrick Robbins Yates & Ponton LLP acted as legal counsel...
Better Therapeutics’ $187 Million Merger Agreement with Mountain Crest Acquisition Corp II
Goodwin Procter LLP advised Better Therapeutics, Inc. on the deal. Better Therapeutics, Inc. announced its definitive merger agreement with Mountain Crest Acquisition Corp II (Nasdaq: MCAD;), a...